@gently you presented a thought provoking path! Good studies for either pth analog to evenity or evenity to pth analog are almost non-existent. The serial anabolic exposure from pth analog to evenity to pth analog calls for a veteran bone specialist's attention. A bold yet innovative idea to say the least. Are there any conceptual bases to back it up? Or, do you see a clear advantage in the absence of an antiresorptive (either reclast or prolia in this case), given anny's need for a quick boost in bmd (hence a reduction of her very high frax score) in a short periods of time?

Curiously, do you think toggling between tymlos and forteo could enhance anabolic effects given their differences in receptor binding?